RNAZ’s Financial Health: Exploring TransCode Therapeutics Inc’s Debt-to-Equity Ratio of 1.79

TransCode Therapeutics Inc (RNAZ) current stock price is $0.22. During the last trading session, the stock soared, reaching $0.2701 after opening at $0.26. The stock’s lowest point was $0.26 before it closed at $0.26.

TransCode Therapeutics Inc’s stock market performance has been somewhat irregular. The 1-year high for the company’s stock was recorded at $23.40 on 12/07/22, with the lowest value being $0.25 on 11/20/23.

Elon Musk just Triggered a BOOM in These Stocks

Something strange is happening in the stock market…. This select group of stocks are going absolutely bananas. And it's all because of Elon Musk. Get your copy of "Top 5 Tech Stocks to Buy in 2024"

Click Here to Download the FREE Report.


52-week price history of RNAZ Stock

Analyzing the 52-week price history of a stock, including its high and low prices, can provide valuable insight into its current status and potential future performance. TransCode Therapeutics Inc’s current trading price is -99.07% away from its 52-week high, while its distance from the 52-week low is -13.97%. The stock’s price range for this period has remained between $0.25 and $23.40. The Healthcare sector company’s shares managed to surpass a trading volume of around 1.89 million for the day, which was noticeably lower compared to the shares’ average daily volume of 6.2 million over the last three months.

Financial Performance and Market Capitalization

TransCode Therapeutics Inc (RNAZ) has experienced a quarterly decline of -86.95% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 4.38M and boasts a workforce of 19 employees.

Moving average and trading volume data

Based on Barchart.com data, the company’s moving average over the 100-day period was 1.2306, with a change in price of -2.2019. Similarly, TransCode Therapeutics Inc recorded 4,076,442 in trading volume during the last 100 days, posting a change of -90.99%.

RNAZ Debt-to-equity ratio analysis

The debt-to-equity (D/E) ratio is a valuable metric that offers insight into a company’s financial health and standing in the market. This ratio is calculated by dividing a company’s current total liabilities by its shareholders’ equity. The D/E ratio illustrates the extent of debt a company is utilizing to support its assets in relation to the value of its shareholders’ equity. At the time of writing, the total D/E ratio for RNAZ stands at 0.13. Similarly, the long-term debt-to-equity ratio is also 0.04.

RNAZ Stock Stochastic Average

As of today, the raw stochastic average of TransCode Therapeutics Inc over the last 50 days is at 2.25%. This shows a declinee from the raw stochastic average of the previous 20 days, which was recorded at 18.68%. Further, the company’s Stochastic %K and %D values for the last 20 days were 8.15% and 6.50%, respectively.

RNAZ Stock Price Performance Analysis

The stock price performance this year has been a mixed bag, which means people have different opinions about whether it’s been good or bad. Some may see it as optimistic, while others may view it as pessimistic. Until today this year the stock’s price performance recorded a decrease of -98.38%. However, over the last six months, the performance has been stronger by -95.95%. The price of RNAZ decreased -41.87% over the last 30 days. And in the last five days, it has fallen by -32.30%.

Leave a Reply

Your email address will not be published. Required fields are marked *

On Key

Related Posts